Stronger immune therapy for high-antibody kidney transplant patients
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial is testing a stronger combination of four immune-suppressing medicines (including mTOR inhibitors) to help prevent rejection in kidney transplant patients who have a high level of antibodies. It aims to see if this approach works better than standard care for these 'sensitized' patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a kidney transplant, and your blood has a high level of antibodies (PRA > 30%) that can make rejection more likely.
- Your body mass index (BMI) is 35 or lower (not severely obese).
- You do not have a history of two specific types of kidney disease (focal segmental glomerulosclerosis or membranoproliferative glomerulonephritis).
- You do not have protein in your urine (protein/creatinine ratio above 0.5 mg/dL) when starting the study drug.
- You do not have very high triglycerides (blood fats) above 300 mg/dL.
- You do not have active hepatitis B, hepatitis C, or HIV, and you have antibodies to CMV (a common virus) at the time of transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
This trial is testing whether a blood test called Prospera can help doctors safely lower the amount of anti-rejection medicines you take after a kidney transplant. It is for people who recently received a kidney and are on standard anti-rejection drugs.
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
This study tests a new medicine called SG301 to see if it can safely treat antibody-mediated rejection (a type of kidney rejection) in people who have had a kidney transplant. It may help stop the immune system from attacking the transplanted kidney.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This study is for people whose first kidney transplant has stopped working and who need to start dialysis. The goal is to see if continuing certain anti-rejection medications can help prevent the body from making antibodies that would make it harder to get another transplant in the future.
Hear when a new Disorder Related to Renal Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.